The Non-Executive of Mirati Therapeutics is Exercising Options

By Carrie Williams

Yesterday it was reported that the Non-Executive of Mirati Therapeutics (MRTXResearch Report), Maria E Martinez, exercised options to sell 7,500 MRTX shares for a total transaction value of $1.53M.

In addition to Maria E Martinez, 10 other MRTX executives reported Sell trades in the last month.

See today’s analyst top recommended stocks >>

Based on Mirati Therapeutics’ latest earnings report for the quarter ending September 30, the company posted quarterly revenue of $11.42 million and GAAP net loss of -$88,163,000. In comparison, last year the company earned revenue of $988K and had a GAAP net loss of $54.17 million. The company has a one-year high of $249.42 and a one-year low of $66.01. Currently, Mirati Therapeutics has an average volume of 673.11K.

Based on 10 analyst ratings, the analyst consensus is Moderate Buy with an average price target of $249.50, reflecting a -17.1% downside.

In the last 30 days, insiders have sold $6.4M worth of MRTX shares and purchased $99.99K worth of MRTX shares. The insider sentiment on Mirati Therapeutics has been negative according to 93 insider trades in the past three months. This sentiment is lower than the average sentiment of company insiders in this sector.

Company insider trades’ information is brought to you by the DailyInsider, a proprietary algorithm that analyzes insider trading activity to detect the most attractive trading opportunities. To subscribe to the DailyInsider visit this page.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Mirati Therapeutics, Inc. is a clinical-stage oncology company. The firm engages in developing a pipeline of oncology products to treat genetic, immunological and epigenetic drivers of cancer in subsets of cancer patients. Its clinical pipeline consists of glesatinib, sitravatinib and mocetinostat. The company was founded on December 13, 1995 and is headquartered in San Diego, CA.